Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven Cancers

Abstract excerpt

<title>Abstract</title> <p>With the advent of approved subtype-specific RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors effective regardless of RAS mutation status is the next major challenge to address clinically prevalent RAS mutations and further overcome RAS-driven acquired resistance to currently available drugs. Here our multi-module drug screening for compounds capable of RAS/...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• Mice
• Mutation
• Neoplasms
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf
• Proto-Oncogene Proteins p21(ras)
• Vemurafenib

Identifiers and source

Literature Corpus work

7d761742-de7c-53b9-8291-418620e522b4

DOI

10.21203/rs.3.rs-3872110/v1